RxDoctor Payments Data

Kathleen Evans, DO

Cardiovascular Disease · Boaz, ALNPI 1790923563

Payments from drug & device makers

$3,324in general payments, 2019–2025

Across 173 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$723
  • Johnson & Johnson$381
  • Novartis$341
  • Pfizer$261
  • Novo Nordisk$178
  • Biotronik Inc.$169
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,16395%
  • Education$1615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,324 in reported general payments places this provider in the 50th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$256,716
Medicare patients
694
Services billed
3,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban301$400,735
EntrestoSacubitril/Valsartan130$162,566
Repatha SureclickEvolocumab133$104,682
XareltoRivaroxaban56$58,772
JardianceEmpagliflozin25$31,978
FarxigaDapagliflozin Propanediol19$27,583
Praluent PenAlirocumab41$23,741
VascepaIcosapent Ethyl22$15,493
BrilintaTicagrelor11$14,900
Ranolazine ErRanolazine147$9,875
Metoprolol Succinate580$7,924
Repatha PushtronexEvolocumab11$6,372
Flecainide Acetate83$5,191
Rosuvastatin Calcium505$4,607
Valsartan138$4,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$261$400,735301 claims
NovartisEntresto$341$162,566130 claims
Johnson & JohnsonXarelto$381$58,77256 claims
AstraZenecaFarxiga, Brilinta$136$42,48230 claims
Boehringer IngelheimJardiance$32$31,97825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Boaz

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →